Dark

IRWD
Ironwood Pharmaceuticals, Inc. - Class A
stock NASDAQ

At Close

Jul 17, 2026 3:59:56 PM EDT

3.85USD-0.517%(-0.02)1,803,988

0.00Bid 0.00Ask 0.00Spread

Pre-market

Jul 17, 2026 9:27:30 AM EDT

3.83USD-1.034%(-0.04)500

After-hours

Jul 17, 2026 4:00:30 PM EDT

3.86USD+0.260%(+0.01)449,095

OverviewOptionsHistoricalExchangesShortsNews

Jan 10, 2022

07:22AM EST Ironwood Pharmaceuticals Expects FY21 Sales At High End Of $390M-$410M Guidance Range Benzinga

07:20AM EST Ironwood Pharmaceuticals Provides Update on FY 2021 Financial Guidance and Announces FY 2022 Financial Guidance Business Wire

Jan 5, 2022

07:30AM EST Ironwood Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference Business Wire

Dec 1, 2021

07:52AM EST Ironwood Pharmaceuticals, Inc. (IRWD), a GI-focused healthcare company, announced Wednesday the appointment of Sravan Emany as senior vice president, chief financial officer. He will directly report to chief executive officer Thomas McCourt. RTTNews

07:40AM EST Ironwood Pharmaceuticals Appoints Sravan K. Emany As Chief Financial Officer Benzinga

07:35AM EST Ironwood Pharma Appoints Sravan Emany As CFO RTTNews

07:30AM EST Ironwood Pharmaceuticals Appoints Sravan K. Emany as Chief Financial Officer Business Wire

Nov 30, 2021

04:03PM EST Overview Of Value Stocks In The Healthcare Sector Benzinga

Nov 22, 2021

09:45AM EST A Look Into Healthcare Sector Value Stocks Benzinga

Nov 4, 2021

08:19AM EDT The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO Benzinga

07:31AM EDT Ironwood Pharmaceuticals Announces It Will Expand Its Pipeline By Signing An Option Agreement To Acquire An Exclusive License With COUR Pharmaceuticals To Develop And Commercialize CNP-104 For The Treatment Of Primary Biliary Cholangitis In The U.S. Benzinga

07:27AM EDT Ironwood Signs Deal With COUR To Develop And Commercialize CNP-104 For Treatment Of Primary Biliary Cholangitis RTTNews

07:23AM EDT Ironwood Pharmaceuticals Q3 EPS $0.34 Vs. $0.21 Last Year RTTNews

07:22AM EDT Ironwood Sees FY21 Adj. EBITDA $210M+, Sales $390M-$410M vs $408.1M Estimate Benzinga

07:22AM EDT Ironwood Pharmaceuticals Q3 Adj. EPS $0.33 Beats $0.31 Estimate, Sales $103.75M Miss $105.40M Estimate Benzinga

07:15AM EDT Ironwood Pharmaceuticals Reports Third Quarter 2021 Results and Provides Corporate Development Update Business Wire

07:00AM EDT Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S. Business Wire

05:00AM EDT Earnings Scheduled For November 4, 2021 Benzinga

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 25, 2021

07:30AM EDT More than 90% of Surveyed IBS-C Patients Who Had an ER Visit or Hospitalization in the Past Year Identified Abdominal Pain as a Symptom That Led to the Visit, According to Data Announced by Ironwood Pharmaceuticals at ACG 2021 Business Wire

Oct 21, 2021

07:00AM EDT Ironwood Pharmaceuticals to Host Third Quarter 2021 Investor Update Call Business Wire

Oct 18, 2021

10:21AM EDT Overview Of Value Stocks In The Healthcare Sector Benzinga

Oct 12, 2021

08:27AM EDT Morgan Stanley Maintains Equal-Weight on Ironwood Pharmaceuticals, Raises Price Target to $14 Benzinga

Sep 2, 2021

07:30AM EDT Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences Business Wire

Aug 26, 2021

07:44AM EDT Ironwood Pharmaceuticals, Inc. (IRWD) said the FDA approved a revised label for LINZESS modifying the boxed warning for risk of serious dehydration and contraindication against use in children to those less than two years of age. Previously, the boxed warning and contraindication applied to all children less than 18 years of age and less than 6 years of age, respectively. RTTNews

07:16AM EDT Ironwood Pharma Announces FDA Approval Of Revised LINZESS Label RTTNews

07:01AM EDT Ironwood Pharmaceuticals Announces FDA Approval of Revised LINZESS Label Benzinga

07:00AM EDT Ironwood Pharmaceuticals Announces FDA Approval of Revised LINZESS(r) (linaclotide) Label Business Wire

Aug 13, 2021

07:43AM EDT The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO Benzinga

Aug 12, 2021

08:09AM EDT The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma Benzinga

Aug 11, 2021

08:14AM EDT The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering Benzinga

Aug 5, 2021

07:30AM EDT Ironwood Pharmaceuticals Raises FY21 Sales Guidance From $370M-$385M To $390M-$410M Vs. $392.03M Est. Benzinga

07:29AM EDT Ironwood Pharmaceuticals Q2 EPS $0.34 Beats $0.22 Estimate, Sales $104.03M Beat $93.10M Estimate Benzinga

07:21AM EDT Ironwood Pharmaceuticals Q2 EPS $2.39 Vs. $0.16 Last Year RTTNews

07:00AM EDT Ironwood Pharmaceuticals Reports Strong Second-Quarter 2021 Results, Raises Full-Year Guidance Business Wire

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

Aug 3, 2021

07:41AM EDT Ironwood Pharma Appoints John Minardo As Chief Legal Officer RTTNews

07:30AM EDT Ironwood Pharmaceuticals Appoints John Minardo as Chief Legal Officer Business Wire

Jul 30, 2021

07:54AM EDT The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs Benzinga

Jul 29, 2021

08:18AM EDT The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs Benzinga

Jul 22, 2021

04:01PM EDT Ironwood Pharmaceuticals to Host Second Quarter 2021 Investor Update Call Business Wire

Jul 16, 2021

08:54AM EDT Morgan Stanley Maintains Equal-Weight on Ironwood Pharmaceuticals, Raises Price Target to $12 Benzinga

Jun 24, 2021

08:12AM EDT The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO Benzinga

Jun 16, 2021

07:48AM EDT Ironwood Announces That The American Journal Of Gastroenterology Publishes Full Results From Positive LINZESS Trial RTTNews

07:46AM EDT Ironwood Pharmaceuticals Announces The American Journal Of Gastroenterology Publishes Full Results From Positive LINZESS Phase IIIb Trial In Adults With Irritable Bowel Syndrome With Constipation Benzinga

07:45AM EDT Ironwood Pharmaceuticals Announces That The American Journal of Gastroenterology Publishes Full Results from Positive LINZESS(r) (linaclotide) Phase IIIb Trial in Adults with Irritable Bowel Syndrome with Constipation (IBS-C) Business Wire

Jun 8, 2021

09:17AM EDT The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex Benzinga

Jun 7, 2021

04:12PM EDT Ironwood Pharmaceuticals Names Thomas McCourt Permanent CEO Benzinga

04:03PM EDT Ironwood Pharmaceuticals Appoints Thomas McCourt CEO; CFO Gina Consylman To Step Down Jul. 2 Benzinga

04:01PM EDT Ironwood Pharmaceuticals Announces Leadership Updates Business Wire

May 27, 2021

08:24AM EDT The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs Benzinga

May 26, 2021

04:02PM EDT Ironwood Pharmaceuticals Announces Agreement with Teva Involving LINZESS 72 mcg Dosage Strength Benzinga

04:01PM EDT Ironwood Pharmaceuticals Announces Agreement with Teva Involving LINZESS(r) (linaclotide) 72 mcg Dosage Strength Business Wire

May 24, 2021

08:07AM EDT Ironwood Pharmaceuticals Announces More Than a Third of Surveyed IBS-C Patients Reported That Their Symptoms Worsened During COVID-19 Benzinga

08:00AM EDT More Than a Third of Surveyed IBS-C Patients Reported That Their Symptoms Worsened During COVID-19 According to New Survey Findings Presented by Ironwood Pharmaceuticals at Digestive Disease Week(r) (DDW) Business Wire

May 17, 2021

08:39AM EDT Ironwood Pharmaceuticals To Present New Linaclotide Data and Unveil Findings From GI Disease Surveys At Digestive Disease Week 2021 Benzinga

May 6, 2021

07:53AM EDT Ironwood Pharmaceuticals Sees FY21 Sales $370M-$385M Vs. $394.42M Est. Benzinga

07:51AM EDT Ironwood Pharmaceuticals Q1 EPS $0.24 Beats $0.21 Estimate, Sales $88.84M Miss $95.20M Estimate Benzinga

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

07:28AM EDT Ironwood Pharmaceuticals Plans To Repurchase Up To $150 Mln Of Shares RTTNews

07:21AM EDT Recap: Ironwood Pharmaceuticals Q1 Earnings Benzinga

07:17AM EDT Ironwood Pharmaceuticals Announces $150M Buyback Benzinga

07:03AM EDT Ironwood Pharmaceuticals Announces New $150 Million Share Repurchase Program Business Wire

07:00AM EDT Ironwood Pharmaceuticals Reports First Quarter 2021 Results Business Wire

04:17AM EDT Earnings Scheduled For May 6, 2021 Benzinga

Apr 22, 2021

04:01PM EDT Ironwood Pharmaceuticals to Host First Quarter 2021 Investor Update Call Business Wire

Mar 13, 2021

11:45AM EST Last Week's Notable Insider Buys: News Corp, Microsoft, Snowflake, Walmart And More Benzinga

Mar 11, 2021

05:47AM EST Ironwood Pharmaceuticals Director Sarissa Capital Management Reported Purchase of 225,000 Shares @ Avg Price: $10.38/Share in Form 4 Filing on Wednesday Benzinga

Mar 6, 2021

01:14PM EST The Past Week's Most Notable Insider Buys: Editas, Exxon Mobil, Wayfare And More Benzinga

Mar 3, 2021

05:45AM EST Ironwood Pharmaceuticals Director Alexander J Denner Reported Purchase of 1,350,000 Shares @ Avg Price: $9.44/Share in Form 4 Filing Late Tuesday Benzinga

Feb 22, 2021

09:23AM EST Morgan Stanley Maintains Equal-Weight on Ironwood Pharmaceuticals, Lowers Price Target to $11 Benzinga

Feb 18, 2021

08:14AM EST The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout Benzinga

Feb 17, 2021

10:31AM EST Ironwood Pharmaceuticals shares were trading higher after the company reported better-than-expected Q4 EPS results. Benzinga

07:48AM EST Recap: Ironwood Pharmaceuticals Q4 Earnings Benzinga

07:10AM EST CORRECTION: Ironwood Pharmaceuticals Sees FY21 Sales $370M-$385M vs $427.47M Est. Benzinga

07:10AM EST Ironwood Pharmaceuticals Sees FY21 Sales $370M-$385M vs $427.47M Est. Benzinga

07:10AM EST Ironwood Pharmaceuticals Sees FY21 Sales $370M-$385M vs $383.96M Est. Benzinga

07:10AM EST Ironwood Pharmaceuticals Q4 Adj. EPS $0.36 Beats $0.29 Estimate, Sales $111.68M Miss $111.95M Estimate Benzinga

04:34AM EST Earnings Scheduled For February 17, 2021 Benzinga

Feb 9, 2021

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

04:58AM EST Ironwood CEO Steps Down Months After Clinical Trial Failure, Names Thomas McCourt As Interim Chief Executive Benzinga

Feb 8, 2021

04:03PM EST Ironwood Pharmaceuticals Announced That Thomas McCourt Was Appointed As CEO Benzinga

Jan 21, 2021

08:05AM EST The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping Benzinga

Dec 4, 2020

09:48AM EST Ironwood Pharmaceuticals Shares Spike Higher; Traders Circulate M&A Chatter Mentioning AbbVie Interest Benzinga

Nov 6, 2020

12:26PM EST Credit Suisse Maintains Neutral on Ironwood Pharmaceuticals, Raises Price Target to $12 Benzinga

11:35AM EST Morgan Stanley Maintains Equal-Weight on Ironwood Pharmaceuticals, Raises Price Target to $12 Benzinga

Nov 5, 2020

04:25PM EST Ironwood Pharmaceuticals Q3 EPS $0.23 Beats $0.15 Estimate, Sales $103.47M Beat $95.96M Estimate Benzinga

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Sep 30, 2020

09:35AM EDT Benzinga's Top Upgrades, Downgrades For September 30, 2020 Benzinga

05:58AM EDT Wells Fargo Downgrades Ironwood Pharmaceuticals to Equal-Weight, Announces $9 Price Target Benzinga

Sep 29, 2020

07:17AM EDT Ironwood to Discontinue IW-3718 Development Program Following Results from Planned Efficacy Assessment; Company Also Reported Trial Did Not Achieve Statistically Significant Improvement In Heartburn Severity (Primary Endpoint) Benzinga

Aug 7, 2020

09:54AM EDT Morgan Stanley Maintains Equal-Weight on Ironwood Pharmaceuticals, Raises Price Target to $11 Benzinga

Aug 6, 2020

07:57AM EDT The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO Benzinga

07:09AM EDT Ironwood Reinstates FY20 Guidance: Adj. EBITDA $105M+, Sales $360M-$380M vs $362.5M Estimate Benzinga

07:08AM EDT Ironwood Pharmaceuticals Q2 Adj. EPS $0.16 Beats $0.09 Estimate, Sales $89.43M Beat $86.24M Estimate Benzinga

Jul 23, 2020

04:06PM EDT Ironwood Pharmaceuticals to Host Second Quarter 2020 Investor Update Call Business Wire

Jul 21, 2020

07:06AM EDT Ironwood Announces Updates Designed to Strengthen IW-3718 Phase III Program for Refractory Gastroesophageal Reflux Disease Benzinga

Jul 15, 2020

10:34AM EDT Morgan Stanley Maintains Equal-Weight on Ironwood Pharmaceuticals, Lowers Price Target to $10 Benzinga